Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice

Mark Katzenellenbogen,1 Lina Mizrahi,1 Orit Pappo,2 Naama Klopstock,1 Devorah Olam,1 Jasmine Jacob-Hirsch,3 Ninette Amariglio,3 Gideon Rechavi,3 Eytan Domany,4 Eithan Galun,1 and Daniel Goldenberg1

1Goldyne Savad Institute of Gene Therapy and 2Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; 3Institute of Hematology and Sheba Cancer Research Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel; and 4Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel

Abstract

Mouse models of hepatocellular carcinoma (HCC) simulate specific subgroups of human HCC. We investigated hepatocarcinogenesis in Mdr2-knockout (Mdr2-KO) mice, a model of inflammation-associated HCC, using gene expression profiling and immunohistochemical analyses. Gene expression profiling showed that although Mdr2-KO mice differ from other published murine HCC models, they share several important deregulated pathways and many coordinately differentially expressed genes with human HCC data sets. Analysis of genome positions of differentially expressed genes in liver tumors revealed a prolonged region of down-regulated genes on murine chromosome 8 in three of the six analyzed tumor samples. This region is syntenic to human chromosomal regions that are frequently deleted in human HCC and harbor multiple tumor suppressor genes. Real-time reverse transcription-PCR analysis of 16 tumor samples confirmed down-regulation of several tumor suppressors in most tumors. We show that in the aged Mdr2-KO mice, cyclin D1 nuclear level is increased in dysplastic hepatocytes that do not form nodules; however, it is decreased in most dysplastic nodules and in liver tumors. We found that this decrease is mostly at the protein, rather than the mRNA, level.

These findings raise the question on the role of cyclin D1 at early stages of hepatocarcinogenesis in the Mdr2-KO HCC model. Furthermore, we show that most liver tumors in Mdr2-KO mice were characterized by the absence of β-catenin activation. In conclusion, the Mdr2-KO mouse may serve as a model for β-catenin-negative subgroup of human HCCs characterized by low nuclear cyclin D1 levels in tumor cells and by down-regulation of multiple tumor suppressor genes. (Mol Cancer Res 2007;5(11):1159–70)

Introduction

Human hepatocellular carcinoma (HCC) is one of the major health care burdens, the molecular pathogenesis of which is still not well understood. Mouse models of HCC have been widely used to study the molecular mechanisms of the disease and to test new therapeutic approaches. Comparison of global expression patterns of orthologous genes in human and murine HCCs showed that certain mouse HCC models closely reproduce specific subgroups of human HCCs (1, 2). Mdr2-knockout (Mdr2-KO) mice represent a model of inflammation-associated HCC (3). They lack the liver-specific P-glycoprotein responsible for phosphatidylcholine transport across the bile canalicular membrane. The absence of phospholipids from bile results in bile regurgitation into the portal tracts (4), causing portal inflammation and fibrosis that mimic human progressive familial intrahepatic cholestasis (5). Liver inflammation and toxicity induced by bile salts in Mdr2-KO mice lead to the development of hepatocyte dysplasia, and by 16 months of age, virtually 100% of Mdr2-KO mice show liver tumors. It was previously found that both tumor necrosis factor-α and nuclear factor-κB are elevated in inflamed portal tracts of Mdr2-KO mice, and that reduction of tumor necrosis factor-α levels or nuclear factor-κB inactivation prevented tumor development, providing a rational link between inflammation and tumorigenesis in this HCC model (6).

We have recently shown that the precancerous stages of liver disease in the Mdr2-KO mice are characterized by induction of many oncoproteins, on one hand, and by multiple protective mechanisms, including up-regulation of many anti-inflammatory and antioxidant genes, on the other hand (7). We have also revealed an age-dependent progressive deregulation of genes that control lipid metabolism; this effect is probably responsible for the
frequent appearance of steatotic dysplastic nodules in the livers of Mdr2-KO mice at 12 months of age. Here, we continue our study on the molecular mechanisms of hepatocarcinogenesis in Mdr2-KO mice by characterizing the cancerous stage of liver disease in this HCC model. We compare the results of the global gene expression profiling of tumors and nontumorous liver tissues from Mdr2-KO mice at 16 months of age with other published data on global expression profiling of mouse HCC models and human HCC samples (1). We determine the dynamic changes in Mdr2-KO livers between mice at 12 and 16 months of age and the essential differences between tumorous, nontumorous, and control liver tissues of Mdr2-KO mice at 16 months of age. The most important microarray findings were confirmed by real-time reverse transcription-PCR (RT-PCR) and by immunohistochemistry on the expanded set of Mdr2-KO liver tumors.

We show that the Mdr2-KO HCC model shares many deregulated HCC-associated genes and pathways with human HCC and is more similar to human HCC cases characterized by better survival (8). We show that Mdr2-KO tumors are characterized by down-regulation of transcripts of multiple tumor suppressor genes and by the absence of β-catenin activation. We also show an intriguing pattern of nuclear staining of cyclin D1 in hepatocytes, which raises a question about the role of this well-known oncogene in hepatocarcinogenesis in the Mdr2-KO HCC model.

Results

Liver Tumor Development

We have previously described that livers of Mdr2-KO mice at 12 months of age were characterized by disrupted lobular structure and appearance of dysplastic nodules, some of them being steatotic (7). The number and size of visible liver tumors in Mdr2-KO mice increased gradually with age. At 16 months of age, almost all Mdr2-KO mice had at least one tumor with a diameter of at least 0.5 cm. In rare cases, tumors could also be found in mice between the ages of 9 and 12 months.

The number of steatotic degenerated hepatocytes also increased with age, and a significant proportion of tumors were steatotic as well. We have analyzed 21 tumor tissue samples from 10 Mdr2-KO males at 16 months of age: for 11 tumors, both formalin-fixed and frozen tissue samples were analyzed; for additional 5 tumors, only formalin-fixed tissue samples were accessible; and for another 5 tumor samples, only frozen tissue samples were accessible (Table 1). Most tumors were well-differentiated HCC as determined by their aberrant growth patterns (thick trabeculae, acinar, and solid growth) and absence of portal tracts. Hepatocyte variability in nuclear size was similar to that in surrounding nontumorous liver tissue. Some tumors were also classified as moderately differentiated HCC, based on predominantly trabecular and solid growth patterns, prominent nuclei observed in >50% of hepatocytes, and marked hepatocyte pleomorphism compared with surrounding nontumorous liver tissue. Number of mitoses observed in tumors varied from 5 to 56 per 50 high-power fields (Table 1).

Common Characterization of Gene Expression in Tumors

The liver RNA samples from six Mdr2-KO tumors, six nontumorous liver tissues (four matched and two unmatched), and three control heterozygous mice at 16 months of age were subjected to gene expression profiling using the genome-scale Affymetrix Mouse Genome 430 2.0 Array. Cluster analysis (9, 10) of the expression profiling data revealed increased heterogeneity of samples as follows: tumorous > nontumorous > heterozygous controls (Fig. 1). This analysis enabled separation of heterozygous samples from Mdr2-KO nontumorous tissues in the space of all the involved genes (these two groups form two fairly distinct clusters). On the other hand, the tumors exhibited high variability and differed from each other. A similar separation of tumor samples was obtained using the clusters of genes with tendency to down-regulation in tumors (Supplementary Fig. S1). These gene clusters separated tumors from both nontumorous tissues and the heterozygous controls.

The clustering results were in accord with the results of supervised analysis (Fig. 2) showing that (a) genes down-regulated in tumors were more statistically significant for separating tumors from nontumorous liver samples than genes up-regulated in tumors, and (b) most genes differentially expressed between nontumorous tissues and heterozygous controls were also differentially expressed between tumors and heterozygous controls, but not vice versa.

Functional Analysis of Differentially Expressed Genes

A substantial fraction of genes differentially expressed in nontumorous tissues of Mdr2-KO mice, when compared with Mdr2-heterozygotes at age 16 months (Supplementary Table S1), was also differentially expressed in Mdr2-KO tissues when compared with Mdr2-heterozygotes at 3 and 12 months of age (7). The common fraction of genes up-regulated both at 12 and 16 months of age was enriched with “cell adhesion”, “cell communication”, and “defense response” genes and contained many potential oncogenes discussed previously (7). The functional study of differentially expressed genes in 16-month-old mice using pathway-oriented and Gene Ontology enrichment analyses revealed progressive down-regulation of liver-specific genes in tumors and Mdr2-KO nontumorous liver tissues compared with heterozygous controls. The most significantly enriched fractions among genes up-regulated in tumors compared with heterozygous tissues were genes related to such Gene Ontology biological processes as “cell proliferation”, “cytoskeleton organization and biogenesis”, and “cell adhesion”. The latter category was also the most enriched among the genes up-regulated in Mdr2-KO nontumorous tissues compared with heterozygotes. Remarkably, the majority of the discovered cell cycle–related genes up-regulated in tumorous and nontumorous Mdr2-KO samples compared with heterozygous controls were involved in the advanced stages of mitosis. Several transcriptional targets of β-catenin, including specific markers of its activation (11, 12), were down-regulated in most Mdr2-KO tumors. Analysis of the known transcriptional targets of other oncogenic pathways showed no convincing evidence of activation in Mdr2-KO tumors of p53, Rb, or Myc regulatory pathways. Several genes that were previously shown to correlate with p53 staining in human HCC (13) were coordinately differentially regulated between tumor samples and heterozygotes in some Mdr2-KO tumor samples. However, immunohistochemical staining of 16 tested Mdr2-KO liver tumors (listed in Table 1) with anti-p53 antibody did not reveal p53 accumulation in any of them (not shown).
Chromosomal Analysis

Chromosomal aberrations are frequent in liver cancer (14) and can be a reason for the variability of gene expression profiles in tumors. Recently, it was shown that an approximate evaluation of DNA ploidy of large chromosomal regions may be deduced from the gene expression profile based on the suggestion that a deleted (or an amplified) region has a tendency to decrease (or increase) the average expression levels.

**TABLE 1. Characterization of Liver Tumors of 16-Month-Old Mdr2-KO Mice**

<table>
<thead>
<tr>
<th>Tumor No.</th>
<th>Tumor Diameter (cm)</th>
<th>Tumor Grade</th>
<th>Mitoses per 50 HPF</th>
<th>Gene Expression Relative to the Matched Nontumorous Liver Tissue*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cyclin D1</td>
</tr>
<tr>
<td>49T1</td>
<td>&gt;1.3</td>
<td>Well</td>
<td>5</td>
<td>Down</td>
</tr>
<tr>
<td>84T1</td>
<td>&gt;1.3</td>
<td>Well</td>
<td>7</td>
<td>Down</td>
</tr>
<tr>
<td>85T1</td>
<td>0.5-0.7</td>
<td>Well/mod.</td>
<td>4</td>
<td>Down</td>
</tr>
<tr>
<td>85T3</td>
<td>0.5-0.7</td>
<td></td>
<td></td>
<td>Down</td>
</tr>
<tr>
<td>93T1</td>
<td>1.1-1.5</td>
<td>Well</td>
<td>18</td>
<td>Down</td>
</tr>
<tr>
<td>93T2</td>
<td>0.5-0.7</td>
<td>Well</td>
<td>7</td>
<td>Down</td>
</tr>
<tr>
<td>94T1</td>
<td>0.5-0.7</td>
<td>Well</td>
<td>9</td>
<td>Down</td>
</tr>
<tr>
<td>96T1</td>
<td>&gt;1.3</td>
<td>Well</td>
<td>5</td>
<td>Down</td>
</tr>
<tr>
<td>96T2</td>
<td>0.5-0.7</td>
<td>Well/mod.</td>
<td>56</td>
<td>Down</td>
</tr>
<tr>
<td>94T1</td>
<td>0.5-0.7</td>
<td>Well/mod.</td>
<td>25</td>
<td>Down</td>
</tr>
<tr>
<td>704T1</td>
<td>&gt;1.3</td>
<td>Well</td>
<td>19</td>
<td>Down</td>
</tr>
<tr>
<td>705T2</td>
<td>&gt;1.3</td>
<td>Mod.</td>
<td>5</td>
<td>Down</td>
</tr>
<tr>
<td>706T1</td>
<td>&gt;1.3</td>
<td>Well</td>
<td>6</td>
<td>Down</td>
</tr>
<tr>
<td>706T2</td>
<td>1.1-1.3</td>
<td>Well</td>
<td>25</td>
<td>Down</td>
</tr>
<tr>
<td>706T3</td>
<td>0.8-1.0</td>
<td>Well</td>
<td>15</td>
<td>Down</td>
</tr>
<tr>
<td>707T2</td>
<td>&gt;1.3</td>
<td>Well</td>
<td>36</td>
<td>Down</td>
</tr>
<tr>
<td>707T3</td>
<td>0.5-0.7</td>
<td>Well</td>
<td>6</td>
<td>Down</td>
</tr>
</tbody>
</table>

**NOTE:** Tumors that were analyzed by gene expression profiling are shown in boldface. Abbreviation: HPF, high-power field (x200). *Results of the real-time RT-PCR. Only genes down-regulated or up-regulated at least 2-fold are shown. †Tumors represented by frozen samples only. ‡Tumors represented by histologic samples only.

**FIGURE 1.** Two-dimensional clustering of gene expression data. The Mdr2-KO data set had been preprocessed by filtering of the valid Affymetrix probes with a SD filter. The 7,167 probes possessing SD for log 2 transformed values higher than 0.3 in all samples were submitted to SPC algorithm incorporated into CTWC tool. The samples include six Mdr2-KO tumorous samples (marked T), six Mdr2-KO nontumorous samples (marked N), and three heterozygous control samples (marked H). A. The color-coded expression matrix with aligned dendrograms of samples (left) and genes (above). The height of dendrogram branches represents the sensitivity variable (temperature) in SPC clustering algorithm. B. The color-coded matrix of the standardized Euclidean distances between the analyzed samples. The order of samples in A and B is identical.
Analysis of genome position–specific deviations of average gene expression in our data revealed multiple areas of up-regulation and down-regulation in tumor samples, including the longest common region of down-regulation, which was localized on chromosome 8 (Fig. 3) and found in three of the six tested tumors. Calculation of the approximate boundaries of this down-regulated ("presumed deleted") region enabled us to map its syntenic regions in the human genome. The presumed deleted region in mice was syntenic to human chromosomal areas known to be frequently deleted in HCC: 4q2, 8p2, 16q1, and 16q2 (14, 16). These regions, both in mice and in humans, contain several genes whose loss of heterozygosity, mutations, or down-regulation was shown to be associated with HCC and other types of cancer: Pdgfrl (17, 18), Vps37a (19), Wwox (20), Cdh1 (21), Rbl2 (22), and Cbfa2t3 (23). We confirmed reduction of copy numbers of the chromosomal region containing the Cdh1 gene (or its loss) in all three tumor samples for which this deletion was presumed by semiquantitative PCR (Supplementary Fig. S2).

Comparison with Published Data

Gene expression patterns of tumorous and nontumorous liver tissue samples of Md2-KO mice were compared with those of previously published murine HCC models. For this purpose, the Affymetrix expression data set of the Md2-KO model was converted into a format comparable to that of two-color spotted arrays (see Materials and Methods). Hierarchical cluster analysis of the joint data set containing data of Md2-KO and other murine HCC models, filtered by variance criteria, enabled separation of all murine HCC models into three large clusters: cluster A, similar to human HCC with "poor survival"; and a cluster having limited relevance to human HCC, in full accordance with previously published results (1). Cluster B comprised E2f1, Myc, and Myc/E2f1 models, as well as the Md2-KO subcluster (Fig. 4).

Ordering the samples belonging to both cluster A and cluster B, according to their similarity in the space of the 500 most variable genes with the help of the SPIN application (24), resulted in a marginal position of Myc/transforming growth factor α and DENA model samples (cluster A) and dispersion of most Md2-KO samples among the samples of cluster B (Supplementary Fig. S3). Remarkably, Md2-KO samples were ordered in a way that could be related to tumor progression: the nontumorous samples were the most distant from the cluster A end, and the two samples expressing α-feto protein, M55T and M56T, were interspersed with the marginal cluster A samples.

Analysis of the distances between average expression profiles of different models showed the proximity of Md2-KO samples to E2f1 and Myc/E2f1 models (Supplementary Fig. S4A). The similarity with the E2f1 model was higher for Md2-KO nontumorous tissues samples, mostly on account of a relatively low number of differentially expressed genes obtained from both of these models. There was no significant up-regulation of E2f1-induced genes in the Md2-KO model. The Acox1 model also shared substantial similarity to Md2-KO tumors.

The Md2-KO gene expression data set was also compared with published human HCC data set (8). In full agreement with the above-mentioned results of comparison with murine HCC models (1), again we see that Md2-KO samples (both tumorous and nontumorous) are more similar to human HCC samples with better survival (cluster B in Fig. 4B and Supplementary...
Fig. S4B) than to human samples with poor survival (cluster A in Fig. 4B). The set of genes that were down-regulated in Mdr2-KO tumors versus nontumorous samples, and also in the human HCC versus normal samples, was enriched with metabolic genes, especially the genes involved in the metabolism of amino acids. The common set of up-regulated genes was enriched with genes classified as “cell cycle,” “cell adhesion,” and “extracellular matrix” genes.

A significant number of HCC-associated genes were found to be coordinately deregulated in Mdr2-KO mice and in published human HCC data sets (Supplementary Table S1). The most prominent among them being up-regulated—Axl, Cbr3, Cd36, Lgals1, Lgals3, Jun, and Ubd; down-regulated—Ahcy, Chs, Gnm (three genes encoding enzymes that control S-adenosylmethionine catabolism), C6, C8a, C8b (encoding complement components), and cytochrome P450 genes Cyp1a2, Cyp2e1, Cyp4v3, Cyp8b1 (8, 25-29). Overexpression of the Ubd protein may cause chromosomal instability (30). We confirmed the up-regulation of its transcript in Mdr2-KO livers by real-time RT-PCR: Ubd was highly up-regulated in nontumorous liver tissues (6- to 23-fold compared with Mdr2-heterozygotes) and progressively up-regulated in most tumors (Table 1 and Supplementary Tables S2 and S3).

**Down-Regulation of mRNA Level of Multiple Tumor Suppressor Genes in Tumorous Tissues of Mdr2-KO Mice**

Gene expression profiling revealed down-regulation of multiple tumor suppressor genes in the tumors of Mdr2-KO mice compared with their matched nontumorous samples. Twenty-six genes annotated as “tumor suppressors” were down-regulated in at least one of the six tested tumors; 12 among them were down-regulated in at least two tumors and 8 were down-regulated in at least three tumors. We carried out real-time RT-PCR analysis of seven genes from the latter set on 16 tumorous RNA samples, including those 6 samples subjected to gene expression profiling. This analysis revealed that four genes (Cdh1, Dleu2, Plag1, and Rbl2) were down-regulated in at least 6 tumors (Table 1). Genes Cdh1 and Rbl2 were mapped inside the presumed deleted region on murine chromosome 8 (discussed above). Among the 16 tested tumors, 11 had down-regulation of at least two tumor
suppressor genes, 7 had down-regulation of at least three tumor suppressor genes, and 4 tumors had down-regulation of at least four tumor suppressor genes. Only 5 tumors exhibited no down-regulation of any of the seven tested tumor suppressor genes.

Cyclin D1 Nuclear Level Is Decreased in Hepatocytes of Tumors and Most Dysplastic Nodules in Mdr2-KO Mice

We have previously shown that during the precancerous stage, cyclin D1 is overexpressed in the livers of Mdr2-KO mice both at the mRNA (Affymetrix array) and protein (Western blot) levels (7). In the current work, we studied the cellular and cytoplasmic or nuclear localization of cyclin D1 by immunohistochemistry. High levels of nuclear cyclin D1 were found in hepatocytes of Mdr2-KO in all lobular zones during the precancerous stage at all tested ages: 3, 6, 9, and 12 months (data for 3 and 12 months of age are presented in Fig. 5A). In the appropriate heterozygous controls, nuclear cyclin D1 staining has been observed only in a small fraction of hepatocytes in zone 2 (Fig. 5A, bottom row). The strongest nuclear cyclin D1 staining has been found in dysplastic hepatocytes that do not produce nodules, both in the cases of large-cell and small-cell dysplasia. After 9 months of age, dysplastic nodules appeared in the livers of Mdr2-KO mice. Most of these nodules were characterized by a significant decrease of nuclear cyclin D1 level in hepatocytes (Fig. 5B). Similarly, a significant decrease of nuclear cyclin D1 level was observed in all tested liver carcinomas of Mdr2-KO mice (more than 30 tumors in more than 20 animals were screened; typical example is shown in Fig. 5C). Average inclusion of bromodeoxyuridine (BrdUrd) in liver tumors was ~3-fold.
higher than that in matched nontumorous regions (Fig. 5C and D), and the number of BrdUrd-positive hepatocytes directly correlated with the number of cyclin D1−negative hepatocyte nuclei (Fig. 5D), showing a higher proliferation rate of tumors with decreased nuclear cyclin D1 level. Global gene expression profiling revealed that cyclin D1 mRNA levels in nontumorous tissues of Mdr2-KO mice were ~4-fold higher than those in heterozygous controls, and remained high, although variable, in most tumorous samples. Only in one sample, D93T1, the cyclin D1 mRNA level was down-regulated compared with the matched nontumorous sample. Real-time RT-PCR of 16 tumorous RNA samples (including 6 that were subjected to Affymetrix arrays) showed down-regulation of cyclin D1 mRNA level in four samples only (Table 1). Thus, down-regulation of cyclin D1 in most liver tumors of Mdr2-KO mice takes place at the protein, rather than the mRNA, level.

Activation of the Wnt signaling is known to induce cyclin D1 expression. Gene expression profiling of six HCC tumors revealed a tendency toward down-regulation of the Wnt signaling in most of these tumors (see above). To confirm these findings and to test a correlation between cyclin D1 and β-catenin localization, we carried out β-catenin immunohistochemistry. All tested HCC tumors of Mdr2-KO mice at 16 months of age were characterized by decreased membranous staining and absence of cytoplasmic or nuclear β-catenin staining. Rare foci with high cytoplasmic β-catenin level and scattered hepatocytes with high nuclear β-catenin level were found preferentially in nontumorous liver regions (Supplementary Fig. S5, top row). Overall, there was no correlation between nuclear cyclin D1 level and nuclear or cytoplasmic β-catenin level; in some cases, an inverse correlation was observed (Supplementary Fig. S5). Immunohistochemistry of E-cadherin in 16-month-old Mdr2-KO mice confirmed its expression profiling data obtained by microarrays: increased expression in nontumorous tissues and decreased expression in most tumors (Supplementary Fig. S6). Whereas Mdr2-heterozygous mice preserved the typical perportal pattern of E-cadherin expression (Supplementary Fig. S6, top row; ref. 31), in nontumorous liver tissues of Mdr2-KO mice, E-cadherin was highly expressed in zones 1 and 2, and sometimes even in zone 3 (Supplementary Fig. S6, middle row). In tumors, however, its expression pattern was more heterogeneous: mostly decreased (Supplementary Fig. S6, bottom row) but well expressed in 5 of 16 tested tumors, similarly to human HCCs (21). Overall, there was no correlation between E-cadherin and β-catenin levels and localization.

In human cancer, an oncogenic alternatively spliced isoform of cyclin D1 was identified (32, 33). In the sequence of the intron 4 of the murine cyclin D1 gene, we found a translation termination signal followed by a polyadenylate signal, similar to the human cyclin D1 gene. However, we could not detect an alternatively spliced cyclin D1 isoform in either tumorous or nontumorous liver tissues of Mdr2-KO mice using RT-PCR with primers flanking the region of the suggested alternative splicing (not shown).

Discussion

Gene expression profiling of liver tissue samples of aged Mdr2-KO mice revealed many features that this HCC model shares with previously published human and mouse HCC data. About 20% of genes differentially expressed in liver tumors of Mdr2-KO mice were also reported to be coordinately differentially expressed in human HCCs (Supplementary Table S1). The genes down-regulated in tumors were enriched with liver-specific genes, whereas genes up-regulated in tumors were enriched with cell cycle–related genes (especially, the genes specific for advanced mitotic stages), similarly with published human HCC data (13, 34). Remarkably, many tumor suppressor genes were down-regulated in three or more of the six tumors that were subjected to the whole genome expression profiling (compared with their matched nontumorous tissues). Real-time RT-PCR analysis of the expression of seven tumor suppressor genes in an expanded tumor set showed down-regulation of at least two tumor suppressors in 10 of the 16 tested tumors. Transcripts of genes Cdh1, Dlu2, Plagl1, and Rb1 were down-regulated each in at least 6 tumors (Table 1). These data emphasize the critical importance of down-regulation of multiple tumor suppressor genes for the switch from nontumorous to tumorous liver tissues.

We analyzed p53 and β-catenin signaling pathways, which are frequently deregulated in HCC. No consistent pattern of differential regulation of p53 transcriptional targets was revealed in Mdr2-KO tumors. Although several genes that were previously shown to correlate with p53 immunostaining in human HCC (13) were also coordinately differentially regulated between tumor samples and heterozygotes in some Mdr2-KO tumor samples, p53 accumulation in Mdr2-KO tumors could not be detected by immunohistochemistry. However, p53 activity can be decreased not only due to mutations in the p53 gene but also due to decreased stability of the p53 protein or interference from other proteins with its function. Thus, it was recently shown that the PTTG1 protein is frequently overexpressed in human HCC and interferes with the ability of p53 to induce apoptosis (35). In the Mdr2-KO microarray data set, the PTTG1 transcript was overexpressed >2-fold in five of the six tested liver tumors (Supplementary Table S1). Further studies are required to reveal the role of the p53 pathway in Mdr2-KO–induced hepatocarcinogenesis. We observed that most transcriptional markers of β-catenin activation were down-regulated in the majority of Mdr2-KO tumor samples. Immunohistochemical analysis revealed no cytoplasmic or nuclear β-catenin staining, as well as decreased membranous staining, in all 16 tested Mdr2-KO liver tumor samples. Nontumorous liver regions of the Mdr2-KO mice were characterized by strongly expanded expression pattern of membranous E-cadherin, which is strictly perportal in normal liver (31). Such expression pattern makes it tempting to speculate that the overexpressed E-cadherin tithrates β-catenin at the plasma membrane, thus decreasing its cytoplasmic and nuclear pools. However, no correlation was found between loss of E-cadherin expression and nuclear accumulation of β-catenin in human HCCs (21) or in other murine HCC models (36). Similarly, in liver tumors of Mdr2-KO mice, there was no correlation between E-cadherin expression level and cytoplasmic or nuclear β-catenin level.

Recently, it was shown that human and murine HCC samples could be divided into two groups that are characterized by either β-catenin activation or genomic instability (37). Based
on the genome positions of differentially expressed genes, we suggested the presence of a prolonged deletion on chromosome 8 in three of the six tested tumor samples. Deletions in chromosome 8 had already been described in mouse HCC models (38). The presumed deletion in murine chromosome 8 is syntenic to human chromosomal regions, which are frequently deleted in human HCC and contain several tumor suppressor genes. We confirmed deletion of the chromosomal region containing the Cdh1 gene, which encodes E-cadherin, in all three presumed liver tumor samples by semiquantitative PCR. One of the possible candidates connecting the escape from mitotic arrest with chromosomal instability is the Ubd (Fat10) gene, which was highly up-regulated in all nontumorous and in most tumors of Mdr2-KO liver samples (Table 1 and Supplementary Tables S2 and S3). Up-regulation of the Ubd expression was reported in human HCC (39) but not in previously published murine HCC models. Ubd was shown to bind a spindle checkpoint protein, Mad2L1 (which was also up-regulated in Mdr2-heterozygotes). Such disturbances in the metabolism of S-adenosylmethionine, a universal donor of methyl groups, may cause changes in the methylation pattern of DNA and histones affecting expression pattern of multiple genes (41).

It was previously shown that based on gene expression profiles, mouse HCC models may be divided into two groups: more similar and less similar to human HCC cases (1). Using the cross-platform and cross-species analyses, we showed that (a) the Mdr2-KO model co-clusterizes with mouse HCC models that are more similar to human HCCs, and (b) most Mdr2-KO liver samples were more similar to the better-survival human HCC samples and better-survival–like mouse models (1). Among the existing murine HCC models, the Mdr2-KO mice are most similar to the E2F1-transgenic model. However, the common differentially expressed genes of Mdr2-KO and E2F1-transgenic mice were not enriched with E2F1 transcriptional targets. Both Mdr2-KO and E2F1-transgenic mice are characterized by progressive steatosis. In E2F1-transgenic mice, the transcription factor Srebp1 (Srebf1) was recently identified as a candidate responsible for induction of lipogenic enzymes (42).

However, most analyzed liver tumors of Mdr2-KO mice did not show a consistent pattern of up-regulation of Srebf1 target genes, as was the case in tumors of E2F1-transgenic mice. Despite the difference in molecular mechanisms that determine the hepatocarcinogenesis in these two HCC models, they both show that liver steatosis is an important risk factor for liver cancer, similarly to what is known for human HCC (43).

We have recently shown that in the livers of Mdr2-KO mice, cyclin D1, a known oncogene, is overexpressed both at the mRNA and protein levels in the early and late precancerous stages (7). In the current study, we show that at the cancerous stage of liver disease, the nuclear level of cyclin D1 is increased in dysplastic hepatocytes that do not form discrete nodules but is decreased in most dysplastic nodules, especially in well-differentiated HCC. This expression pattern is independent of animal age (mice at ages 12, 14, 16, and 18 months were tested), which raises a question about the role of cyclin D1 at different stages of hepatocarcinogenesis in Mdr2-KO mice. Cyclin D1 is overexpressed at relatively early stages of different human tumors; in many cancers including HCC, its overexpression is associated with poor prognosis (44). In human HCC, the cyclin D1 level compared with surrounding nontumorous tissue correlated with tumor grade: mostly not overexpressed in well-differentiated HCC and progressively up-regulated in moderately and poorly differentiated HCC (45-47). Ultrasonography and subsequent immunohistochemical analyses of small human HCC nodules showed that...
overexpression of cyclin D1 protein was found in only 5% of hyperechoic HCCs but in 38% of hypoechoic HCCs (mainly in moderately differentiated tumors; ref. 48). Down-regulation of cyclin D1 in some human HCC types has also been reported (34, 49, 50). Thus, down-regulation of nuclear cyclin D1 level in dysplastic nodules and in well-differentiated HCC in the livers of Mdr2-KO mice modulates its expression in some subgroups of human HCC, particularly in hyperechoic liver tumors, which are predominantly steatotic (48), as well as in many liver tumors of Mdr2-KO mice. What could be the role of this down-regulation in hepatocarcinogenesis? High levels of cyclin D1 in the cell nucleus during the S phase inhibit DNA synthesis; efficient cell proliferation requires glycogen synthase kinase 3β-dependent phosphorylation of cyclin D1 following its export from the nucleus and subsequent degradation (51). However, the oncogenic alternatively spliced isoform of cyclin D1 lacks the phosphorylation site and remains nuclear (32), showing that at some stage, cancer cells can overcome the inhibition of DNA synthesis by cyclin D1. Remarkably, it was recently shown that in human esophageal adenocarcinoma, the appearance of this alternatively spliced cyclin D1 isoform was associated with increased genomic instability (52). Previously, it was shown that cyclin D1 overexpression induces centrosome and mitotic spindle abnormalities, as well as aneuploidy in murine hepatocytes in vivo and in human breast epithelial cells in vitro (53). These findings reveal another potential oncogenic mechanism of prolonged nuclear accumulation of cyclin D1, which takes place in hepatocytes of Mdr2-KO mice.

We hypothesize that cyclin D1 plays different roles at different stages of hepatocarcinogenesis in Mdr2-KO mice. At the precancerous stage, overexpression of cyclin D1 in hepatocyte nuclei engenders a tumor suppressor activity by inhibiting DNA replication in most hepatocytes. Simultaneously, it may
act as an oncogene by inducing aneuploidy in some hepatocytes. The above-mentioned overexpression of the Ubd gene should induce aneuploidy as well. In dysplastic nodules and well-differentiated HCC, some mechanism (e.g., downregulation of the retinoblastoma protein; ref. 54) may cause degradation of the cyclin D1 protein, thus allowing uncontrolled hepatocyte proliferation. At the later stages of moderately and poorly differentiated HCC, tumor cells may acquire an ability to bypass the inhibitory effect of cyclin D1 on DNA synthesis. At these stages, cyclin D1 is frequently overexpressed and acts as an oncogene, stimulating increased cell proliferation. Indeed, whereas most tested liver tumors in Mdr2-KO mice were well differentiated, some of them contained foci of less differentiated, “primitive” hepatocytes, which had strong nuclear cyclin D1 staining (data not shown).

Expression of cyclin D1 is regulated by multiple factors both at mRNA and protein levels (Fig. 6). Both in human and mouse HCC, activation and/or mutations of β-catenin are significantly associated with cyclin D1 overexpression. Analysis of β-catenin transcriptional targets revealed absence of activation of the classic Wnt-pathway in most HCC tumors of Mdr2-KO mice. Both in tumorous and nontumorous liver tissues, levels of cyclin D1 mRNA did not correlate with expression patterns of β-catenin targets, and nuclear level of cyclin D1 protein in hepatocytes did not correlate with nuclear or cytoplasmic level of β-catenin. Thus, in the Mdr2-KO liver, cyclin D1 is up-regulated not due to activation of β-catenin. Further studies are required to reveal the factors that regulate cyclin D1 expression in Mdr2-KO hepatocytes and the role of cyclin D1 in Mdr2-KO–induced hepatocarcinogenesis.

In conclusion, we show that the Mdr2-KO mouse may be used as a model for human HCCs that are characterized by the absence of β-catenin activation, by low nuclear cyclin D1 levels in tumor hepatocytes, and by down-regulation of multiple tumor suppressor genes. The role of processes such as inflammation and steatosis in hepatocarcinogenesis and of HCC-associated regulatory proteins such as nuclear factor κB (6), cyclin D1, E-cadherin, Ubd and proteins, which regulate methylation, can be studied in this HCC model.

Materials and Methods

Animal Experiments

Founders of the FVB.129P2-Abcb4<sup>tm1Bor</sup> (Mdr2-KO; old name FVB.129P2-Pgv24<sup>tm1Bor</sup>) and the wild-type FVB/NJ mice were purchased from The Jackson Laboratory. Colonies of both strains were maintained under specific pathogen-free conditions at the Animal Facility of The Hebrew University Medical School. The F<sub>1</sub> hybrids produced by breeding of an FVB.129P2-Abcb4<sup>tm1Bor</sup> male and an FVB/NJ female were used as age-matched controls. Harvesting of mouse liver tissues and blood analysis for levels of liver enzymes were done as described previously (7). BrdUrd (100 mg/kg; Sigma) was injected i.p. twice: 4 and 2 h before liver resection. All animals received humane care and were kept in a specific pathogen-free facility according to the guidelines established by the U.S. National Academy of Sciences and published by the NIH.

Gene Expression Profiling

Total RNA was isolated from frozen liver tissues with Trizol reagent (Invitrogen) as described by the manufacturer and subjected to genome-scale gene expression profiling using Mouse Genome Array 430A (Affymetrix, Inc.). The gene expression values were extracted using the MAS 5.0 software and, after thresholding and filtering procedures, were submitted to fold change and cluster analyses (see Supplementary Methods for details). The expression data are accessible on the GEO site, represented according to the MIAME requirements.

Comparison with Published Data Sets

The Affymetrix expression data for the Mdr2-KO model were presented as data on gene differential expression (in the format of the output of two-color spotted arrays) by calculating the log ratio of the expression values in Mdr2-KO samples to the average of Mdr2-KO heterozygous controls. The joint data sets containing our data and the data of other research groups were created and analyzed as described in Supplementary Methods.

Chromosomal Analysis

Smoothed fold change values have been calculated for all annotated genes that were relevant for position-specific fold change analysis and plotted against their chromosomal positions (see Supplementary Methods for details).

Real-time RT-PCR

Reverse transcription of total RNA was done using the Moloney murine leukemia virus reverse transcriptase enzyme and random hexamer primers from Promega. Real-time PCR was run in triplicates using the TaqMan Universal PCR Master Mix, primers and probe sets, and the ABI PRISM 7700 Sequence Detector system from Applied Biosystems. Threshold cycle numbers (C<sub>T</sub>) were determined with Sequence Detector Software (version 1.6; Applied Biosystems) and transformed.
using the $\Delta C_t$ method as described by the manufacturer. The relative quantification values for each gene were normalized against the endogenous “housekeeping” gene $\beta$-actin, which was one of the most uniformly expressed genes in all RNA samples subjected to global gene expression profiling.

**Immunohistochemistry**

Immunostaining was done on 4-μm-thick formalin-fixed paraffin-embedded liver tissue sections by standard procedures. Antigen retrieval was done with citrate buffer (pH 6.0; $\beta$-catenin, p53, and BrdUrd), Tris-EGTA buffer (pH 9.0; E-cadherin), or glycine buffer (pH 9.0; cyclin D1) in a microwave by boiling (BrdUrd) or using a pressure cooker (cyclin D1, $\beta$-catenin, E-cadherin, and p53). Primary antibodies were cyclin D1 (RMAB003; Diagnostic Biosystems), $\beta$-catenin (clone 14; BD Biosciences), E-cadherin (24E10; Cell Signaling Technology, Inc.), p53 (CM5p; Vision Biosystems/Novocasta), and BrdUrd (Mo744; DAKO). Secondary antibodies were from DAKO or Zymed. Staining was developed with diaminobenzidine and BrdUrd (Mo744; DAKO). Secondary antibodies were from DAKO or Zymed. Staining was developed with diaminobenzidine using the kit from DAKO.

**Acknowledgments**

We thank our colleagues from Hadassah-Hebrew University Medical Center: Prof. Leslie Ann Mitchell and Dr. Amnon Peled (Goldyne Savad Institute of Gene Therapy) for useful discussions; Dr. Eli Pikarsky (Department of Pathology) for his help in immunohistochemistry techniques and sharing unpublished data; Prof. Yinon Ben-Neriah (The Lautenberg Center for Immunology) for providing antibodies, protocol, and a positive control for p53 immunostaining; Ariel Israel, Carol Levy, and Mery Clausen (Goldyne Savad Institute of Gene Therapy) for their assistance in bioinformatics, work with mice, and manuscript preparation, respectively.

**References**


Molecular Cancer Research

Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice

Mark Katzenellenbogen, Lina Mizrahi, Orit Pappo, et al.


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/5/11/1159

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2007/12/07/5.11.1159.DC1

Cited articles
This article cites 54 articles, 18 of which you can access for free at:
http://mcr.aacrjournals.org/content/5/11/1159.full.html#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/5/11/1159.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.